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Abstract
Background: MicroRNAs (miRNAs) have emerged as important gene regulators and are recognized as key players in
tumorigenesis. miR-145 is reported to be down-regulated in several cancers, but knowledge of its targets in colon cancer
remains limited.
Methodology/Principal Findings: To investigate the role of miR-145 in colon cancer, we have employed a microarray based
approach to identify miR-145 targets. Based on seed site enrichment analyses and unbiased word analyses, we found a
significant enrichment of miRNA binding sites in the 39-untranslated regions (UTRs) of transcripts down-regulated upon
miRNA overexpression. Gene Ontology analysis showed an overrepresentation of genes involved in cell death, cellular
growth and proliferation, cell cycle, gene expression and cancer. A number of the identified miRNA targets have previously
been implicated in cancer, including YES, FSCN1, ADAM17, BIRC2, VANGL1 as well as the transcription factor STAT1. Both YES
and STAT1 were verified as direct miR-145 targets.
Conclusions/Significance: The study identifies and validates new cancer-relevant direct targets of miR-145 in colon cancer
cells and hereby adds important mechanistic understanding of the tumor-suppressive functions of miR-145.
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Introduction
In past years small non-coding RNAs have been recognized as
important gene regulators [1–4]. miRNAs are an abundant group
of endogenous small non-coding RNAs that function as regulators
of protein encoding genes through translational repression and/
or degradation of their target mRNAs [1]. Extensive miRNA
research has revealed that miRNAs are involved in the regulation
of numerous key cellular functions such as metabolism, cell
proliferation, tumorigenesis, apoptosis, development and differen-
tiation [1,3,4]. To regulate target mRNAs mature miRNAs are
bound to AGO proteins and guide the AGO-associated RNA
induced silencing complex (RISC) to mRNA targets through
imperfect base pairing between the miRNA and the target. This
often involves perfect base paring between the 59 end of the
miRNA strand and its target, also termed the seed site.
Bioinformatics analyses suggest that each miRNA can control
hundreds of target genes in humans and it has recently been
reported that over 60% of protein encoding genes are under
selective pressure to maintain pairing with miRNAs, indicating
that miRNAs have the potential to regulate the majority of protein
encoding genes [5].
Inappropriate expression of miRNAs, which regulate genes
functioningaseithertumor-suppressors oroncogenescanultimately
lead to acquisition of the hallmarks of cancer, thus specifying
miRNAs as both tumor-suppressors and oncogenes [3,6,7]. Specific
changes in miRNA expression levels have been associated with
various types of cancer [8] and a large number of miRNAs are
localized in so-called cancer-associated genomic regions, which are
frequently exposed to changes in cancer cells [9]. However, in
contrast to the large number of miRNAs that has been identified in
the past years, only relatively few miRNA targets have been
experimentally validated. Given the overwhelming evidence that
miRNAs are important regulators of tumorigenesis [3,6], identifi-
cation of miRNA targets is necessary in order to understand the
mechanistic basis for the involvement of miRNAs in cancer.
miR-145 has frequently been reported as down-regulated in
cancers, including prostate cancer [10,11], bladder cancer [12],
colon cancer [13-18], ovarian cancer [19,20] as well as B-cell
malignancies [21,22], and it has been reported that the genomic
region encoding miR-145 is located in a fragile site often deleted
in cancer [23]. Accordingly, miR-145 overexpression has been
demonstrated to have a growth inhibitory effect [16,17,24,25]
and to suppress anchorage independent growth [16]. It has
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induced by p53 [16]. Here, it was reported that miR-145 targets
c-Myc through imperfect seed base pairing [16] and it was
suggested that p53-mediated downregulation of c-Myc is, at least
partially, due the p53-mediated upregulation of miR-145. Another
study also found an increased level of miR-145 induced by
doxorubicin [26]. However, instead of a transcriptional activation
of miR-145 it was found that p53 activates the processing of
primary miR-145 transcripts into miR-145 precursors [26]. This
phenomenon was not only restricted to miR-145, but also applied
to several other miRNAs with known growth suppressive
functions, indicating p53-mediated regulation of miRNA process-
ing as a way of exerting its tumor-suppressive function [26]. In
addition to c-Myc, miR-145 has also been suggested to target the
human insulin receptor substrate-1 (IRS-1) and type I insulin-like
growth factor receptor (IGF-IR) in colon cancer [25,27]. However,
the specificity of the target interaction was not confirmed by
mutational analysis of the seed sites in either of these cases.
The expression level of miR-145 is induced during differenti-
ation of human embryonic stem cells and miR-145 overexpression
has been demonstrated to impair the pluripotency in human
embryonic stem cells by targeting of OCT4, SOX2 and KLF4 that
are involved in maintaining the self-renewing capacity of human
embryonic stem cells [28]. This role of miR-145 as an inducer of
differentiation in embryonic stem cells is in agreement with the
role of miR-145 as a repressor of growth in cancer cells. A mouse
model designed to investigate the expression pattern of miR-145
revealed expression of miR-145 in multipotent cardiac progenitors
and smooth muscle cells [29] and suggested that miR-145
promotes the differentiation into smooth muscle cells [29].
However, another study showed that mice lacking miR-145 were
viable with no overt abnormalities in smooth muscle cell
differentiation [30], demonstrating the existence of additional
promoters of differentiation.
Taken together, miR-145 appears to have tumor-suppressor
functions when overexpressed in cancer cells and may normally
play a role in differentiation processes. Here, we have focused on
target identification of miR-145 in colon cancer, based on
microarray expression profiles of cells overexpressing miR-145.
Gene Ontology analyses of miR-145 responsive genes confirm
regulation of genes involved in cell death, cell cycle regulation and
cancer. We have identified a number of miR-145 targets that
could be interesting in a cancer context and verified that miR-145
targets YES and STAT1 in colon cancer cells.
Results
Prompted by the numerous reports of miR-145 downregulation
in cancer we sought to identify miR-145 targets that could explain
the role of miR-145 in cancer. To gain insight into the expression
levels of miR-145 in established cell lines, we profiled the
expression levels in a number of cancer cell lines as well as in
non-tumorigenic cell lines (FIGURE S1). The expression profiles
of miR-145 showed that except for MCF10A all tested non-
tumorigenic cells lines expressed miR-145, whereas the expression
levels of miR-145 were very low in all tested cancer cell lines,
supporting previous findings where miR-145 is down-regulated or
lost in cancer. Due to its implications in colon cancer [13–18], we
decided to investigate the role of miR-145 in the colon cancer cell
line DLD-1. Co-transfection of miR-145 duplex with a luciferase
reporter containing a perfect complementary site to the mature
miRNAs resulted in a marked downregulation of the luciferase
activity, demonstrating a highly effective overexpression (FIGURE
S2A). As demonstrated by both crystal violet and MTT growth
assays, overexpression of miR-145 resulted in a decreased cell
proliferation (FIGURE 1 and FIGURE S3).
Identification of miR-145 Targets
Given the indications that miR-145 plays a role in cancer,
together with the limited knowledge of its targets in colon cancer,
the aim was to identify functionally relevant targets that could help
to explain the role of miR-145 in cancer. To achieve this, we used
a microarray based strategy similar to the one previously used to
identify miR-21 targets [31]. DLD-1 cells were transfected with
50 nM miR-145 duplex or mock transfected. Total RNA was
harvested 24 hours post-transfection and analyzed on Affymetrix
HG-U133 Plus 2.0 human arrays. A total of eight arrays were
analyzed. For filtering, uninformative genes with the same
expression level across all arrays (including non-expressed genes)
were removed and the differentially expressed genes, their
corresponding p-values and false discovery rates were calculated
as described in the MATERIALS AND METHODS section.
To determine if the genes regulated upon miR-145 overexpres-
sion were related to specific cellular functions, a search within the
functional annotations in the Ingenuity database (IngenuityH
Systems, www.ingenuity.com) was performed for all miR-145
responsive genes. The top five enriched functional categories of the
Gene Ontology analysis are listed in TABLE 1. Among these
categories are cell death, cellular growth and proliferation, cell
cycle regulation and cancer. Corresponding analyses using
random gene sets generated from Affymetrix HG-U133 Plus 2.0
annotations, in some cases resulted in enrichment of the same
categories that we found enriched in the miR-145 dataset, but with
p-values 10 orders of magnitude higher than in the miR-145
dataset (data not shown).
Seed site enrichment analysis of the occurrences of miR-145
seed sites in the 39UTRs demonstrated a highly significant enrich-
ment among the down-regulated transcripts (FIGURE 2A). The
p-values for the enrichment of miR-145 seed sites (including
7mer, 7mer-1A and 8mer sites) were 1.4?10
221 and 7.6?10
28
when considering the down-regulated transcripts vs. up-regulated
transcripts and down-regulated transcripts vs. no change tran-
scripts, respectively. Two alternative methods of calculating the
seed site enrichment, either as seed site occurrences after
correcting the up, down and no changes sets to the same size or
as seed site occurrences per kb, showed a similar enrichment in the
Figure 1. miR-145 overexpression reduces the proliferative
potential of DLD-1 cells. DLD-1 cells transfected with 50 nM miR-145
duplex exhibit a reduced cell proliferation as measured by crystal violet
growth assay. Data are shown as the mean 6 S.D. of four replicates.
doi:10.1371/journal.pone.0008836.g001
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verifies that the microarray based approach can be used to identify
miRNA targets. When the whole cDNA sequence of the transcripts
was used for seed site enrichment analysis (reported as the
percentage of transcripts with seed sites), we still find a significant
enrichment of seed sites, even though the enrichment is less
pronounced compared to only considering the 39UTR sequences
(FIGURE S5A). A similar analysis of coding sequences and 59UTR
sequences revealed no significant seed site enrichment (FIGURE
S5B and S5C).
Unbiased word analyses of the 39UTR sequences identified the
7mer seed site of miR-145 as the most significantly enriched 7mer
word in the 39UTRs of down-regulated transcripts (TABLE 2).
Several of the other highly enriched words were variations of the
miR-145 seed site and the fourth most enriched word was the 7mer-
1A seed match (TABLE 2). A corresponding 6mer word analysis
also identified miR-145 seed matches as the most significantly
enriched words (FDR,0.005) (FIGURE S6). Plotting the running
sum of the overrepresentation scores of the 7mer seed site in
transcripts ranked according to their logFC clearly showed that the
39UTRs of down-regulated transcripts had a high enrichment of
miR-145 7mer seeds (black line) which was not observed for
permutations of the ranked gene list (red lines) (FIGURE 2B).
Potential miR-145 Targets
Since miR-145 is down-regulated or lost in cancer, re-
introduction of miR-145 would be expected to cause a direct
downregulation of oncogene targets. Indeed, a number of genes
with oncogenic function were down-regulated upon miR-145
overexpression including the Src family member YES and the actin
cross-linking protein FSCN1, which is found in cell surface
projections implicated in cell motility [32]. The metalloproteinase
ADAM17 and a member of the inhibitor of apoptosis (IAP) family
BIRC2 (also known as cIAP1), which both contain 8mer miR-145
seed sites in their 39UTRs, were also observed as down-regulated
upon miR-145 overexpression. In addition, VANGL1 which is
involved in wound healing response of intestinal epithelial cell lines
through promotion of cell migration was also identified as a
putative miR-145 target [33].
Some of the down-regulated genes did not have a miR-145 seed
site in their 39UTR, but instead had one or more a seed sites in the
coding region. STAT1, a well known transcription factor [34,35]
and IQGAP1 a negative regulator of cell-cell adhesions and
stimulator of cell motility and invasion [36], both had miR-145
seed sites in the coding regions of their transcripts. In the case of
STAT1, the miR-145 seed site is located in the second last exon of
the transcript. Since STAT1 was among the most down-regulated
transcripts in the microarray analysis, it was also considered as a
potential target and included in the subsequent investigations. The
previously identified miR-145 targets OCT4, SOX2 and KLF4 in
human embryonic stem cells were not expressed in DLD-1 cells
(data not shown). MYC, ISR-1 and IGF-1R, suggested by others as
miR-145 targets [16,25,27], showed no change in expression level
upon miR-145 overexpression in our dataset (data not shown).
The full list of identified potential miR-145 targets containing seed
sites in their 39UTR is presented in TABLE S1.
Target Validation
We next confirmed the microarray data by quantitative RT-
PCR for seven selected transcripts that were found down-regulated
in the microarray analysis (FIGURE 2C). Notably, STAT1 and
YES, which have miR-145 seed sites in the coding region and
39UTR, respectively, showed a clear down-regulation on the
transcript level upon miR-145 overexpression. To determine
whether miR-145 directly regulates YES and STAT1, luciferase
reporter constructs were cloned. The base pairing between the
miRNA seed sites and the potential mRNA targets are depicted in
FIGURE 3A. In both cases, overexpression of miR-145 resulted in
decreased luciferase activity, indicating that the miRNA can bind
both the YES 39UTR and the STAT1 cDNA and directly mediate
repression (FIGURE 3B). This was not the case with reporter
constructs where the seed sites had been mutated (FIGURE 3B).
To further confirm the miRNA mediated down-regulation of
STAT1 and YES on protein level, western blot analyses were
performed in both DLD-1 cells and HCT116 colon cancer cells.
The overexpression efficiency of miR-145 in HCT116 measured
by luciferase reporter constructs was similar to that observed in
DLD-1 cells (FIGURE S2B). A marked decrease of YES protein
level mediated by miR-145 was observed 48 hours post-transfec-
tion in both DLD-1 and HCT116 cells (FIGURE 3C). A more
subtle, but still clear downregulation of STAT1 mediated by miR-
145 was also observed (FIGURE 3D). Notably, the degree of
STAT1 repression varied between DLD-1 and HCT116 cells,
with the strongest repression of STAT1 observed in DLD-1 cells.
Secondary Effects Due to STAT1 Deregulation
STAT1 is a well characterized transcription factor best
recognized as a transcriptional activator, but examples of negative
transcriptional regulation have also been described [34]. The
STAT1 binding motif as defined by the JASPAR CORE database
[37] is shown in FIGURE S7A. To determine if the miR-145
mediated downregulation of STAT1 also caused a change of the
expression level of STAT1 target genes in the microarray analysis, a
search for STAT1 binding sites in the promoters of the down-
regulated, up-regulated and transcripts with no change in
expression level was conducted. Out of all JASPAR core
transcription factors, STAT1 was the most significantly enriched
binding site both when the down-regulated (p-value=4.18?10
24)
and the up-regulated genes (p-value=1.34?10
24) were compared to
thegenes with no changein expression (TABLE3).Thiswasnot the
case for a permuted STAT1 binding matrix when comparing up-
regulated genes to the genes with no change in expression level
(FIGURE S7B). However, when considering the down-regulated
genes compared to no-change genes, there was also a slight
enrichment of STAT1 permuted binding sites, indicating that some
of the observed effects may be non-specific (FIGURE S7C).
Discussion
miRNAs are emerging as important gene regulators and
intensive research of their functions and targets have revealed a
Table 1. Enriched functional categories among miR-145
responsive genes.
Function P-values*
Number of
Molecules
Cell Death 3.36?10
223–7.86?10
24 514
Cellular Growth and Proliferation 1.13?10
221–6.93?10
24 531
Cell Cycle 3.08?10
220–7.99?10
24 273
Gene Expression 6.16?10
218–7.99?10
24 361
Cancer 9.23?10
217–8.09?10
24 571
*P-values indicating enrichment of functional subgroups within the indicated
functional categories.
doi:10.1371/journal.pone.0008836.t001
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understanding of functional roles of miRNAs in cancers is steadily
increasing, knowledge about miR-145 and its targets in colon
cancer is still largely missing. We hence focused on the
identification of miR-145 targets in colon cancer cells. Supporting
previous findings that miR-145 is down-regulated in tumors
[10–13,15,16,18–21,38–42], a profile of miR-145 expression in
established cell lines demonstrated that expression levels of miR-
145 were drastically reduced in cancer cell lines relative to non-
tumorigenic cell lines. In agreement with reports showing a growth
inhibitory effect of miR-145 [16,17,41], we also observe a growth
reduction of DLD-1 cells upon transient miR-145 transfection,
which implies that miR-145 possesses a tumor-suppressor function
in vitro.
Here, we used microarray profiling upon miR-145 overexpres-
sion as a method of identification of potential targets. Microarray
expression profiles combined with seed site enrichment analysis is
a well established approach used to identify potential miRNA
targets [31,43,44]. It has the advantage over strictly computational
target prediction that it is not only based on the presence of a seed
site and sequence features of the potential target, but takes into
account whether the target is expressed in the considered cell line
and whether the target is regulated on the transcript level. Since
this approach is solely based on changes observed on transcript
Figure 2. Microarray based identification of miR-145 targets. A, The percentages of genes in the up, down (dn) and no-change (nc) sets with
seeds sites in their 39UTRs. Only those 6mers which are not part of a 7mer or 8mer are reported as 6mers and only those 7mers that are not contained
within a 8mer are counted as 7mers. Mean log fold-changes were 0.36, 0.02 and 20.40 for the up, down and no-change sets, respectively. The
p-values are calculated testing the null hypothesis that the proportion of genes with seed sites are the same for the down-regulated and the up-
regulated genes (dn vs. up) or the down-regulated genes compared to the no-change genes (dn vs. nc). P-values for 7mer seed site enrichment were
1.7?10
233 (dn vs. up) and 2.9?10
211 (dn vs. nc). P-values for 7mer-1A seed site enrichment were 3.7?10
218 (dn vs. up) and 7.8?10
27 (dn vs. nc). B,
Unbiased word analysis showing the running sum of the overrepresentation score for the miR-145 7mer seed site in the ranked list of 39UTR
sequences (black line) compared to permutations of the ranked gene list (red lines). Down- and up-regulated genes (defined as genes with FC,21.1
or FC.1.1) in the ranked gene list are indicated in the graph. C, Quantitative RT-PCR validation of the microarray data. Cells were transfected with
50 nM miR-145 duplex or mock transfected and total RNA harvested 24 hours post-transfection. The 39UTRs of IQGAP1 and STAT1 do not contain any
miR-145 seed matches, but both genes contain a 7mer seed match in their coding region. All other miR-145 responsive genes contain at least one
7mer seed site in their 39UTR. The expression level of each transcript is shown relative to the level in mock transfected cells. Data are shown as the
mean 6 S.D. of three replicates.
doi:10.1371/journal.pone.0008836.g002
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not be identified.
Seed site enrichment analysis and unbiased word analysis
showed a clear enrichment of miR-145 seed sites in the 39UTRs
of down-regulated transcripts, confirming our approach to
identify miR-145 targets. We did not observe any enrichment
of miR-145 seed sites in the coding region of down-regulated
transcripts. However, since some of the genes containing seed
sites within the coding region previously had been implicated in
cancer, we speculated that these target candidates may also play a
functional role downstream miR-145. The unbiased word
analysis, used here to evaluate the enrichment of words in
39UTRs according to the logFC of the transcript upon miR-145
overexpression, presents an extremely useful method for visual-
ization of the effects of miRNA overexpression without making
any prejudiced assumption regarding cutoff values. The shape of
the running sum curve shows a sharp peak of the miR-145 7mer
seed sites for the most down-regulated genes suggesting that
target transcript down-regulation to a large part is due to direct
effects of miR-145 targeting. The unbiased word analysis
confirmed previous reports showing that an A at position 1 of
the seed site is beneficial regardless of its potential to base pair
with the miRNA [2,45].
Many of the targets identified here have previously been
implicated in cancer. The enriched functional categories of all
miRNA responsive targets further supported the implication of
miR-145 in cancer and imply that both the direct effects of miR-
145 as well as secondary effects can explain the role of miR-145 in
cancer. A number of genes with oncogenic function, many of
which have also been associated with colon cancer, were identified
as potential miR-145 targets based on the microarray analysis.
These include ADAM17, BIRC2 and VANGL1. ADAM17 has been
reported up-regulated in colon carcinomas and has been shown to
promote the release of epidermal growth factor receptor (EGFR)
ligands from the cell membrane, thus activating EGFR [46].
BIRC2 has been demonstrated to be essential for maintaining
endothelial cell survival and vascular integrity in zebrafish by
activating the formation of the TNF receptor complex I as well as
promoting the degradation of IkB, upon which NF-kB is released
and translocates into the nucleus where it activates pro-survival
genes in endothelial cells [47]. The cell membrane associated
fraction of VANGL1 increases with differentiation and was
demonstrated to co-localize with E-cadherin in human colon cells
[33]. In addition, it was demonstrated that overexpression of
VANGL1 stimulated wound closure of intestinal epithelial cell lines,
whereas siRNA directed against Vangl1 inhibited the migratory
response [33]. Previously reported miR-145 targets including
OCT4, SOX2 and KLF4 involved in the promotion of stem cell
proliferation were not expressed in DLD-1 cells, implying that the
growth inhibitory effect of miR-145 overexpression in DLD-1 cells
is not due to downregulation of these genes. Another key regulator
of cell proliferation, MYC, previously reported as a miR-145 target
showed no change in expression level upon miR-145 overexpres-
sion in our setting.
Experimental validation of YES and STAT1 as miR-145 targets
demonstrated a marked down-regulated on mRNA and protein
level, proving the biological effect of miR-145 on the endogenous
targets. The down-regulation in 39UTR/cDNA luciferase assays
further validates that this is the result of direct interactions, since
mutations of the miR-145 seed sites abolish this down-regulation.
The reason of the different effects of miR-145 in the different
assays is likely due to a lack of direct comparability between these
assays. This difference could also be due to other binding factors
involved in regulation of the endogenous transcript, as these
binding sites are not present in the 39UTR or cDNA fragments
used in the cloned luciferase reporter constructs.
A number of studies have linked increased expression of YES in
cancer with increased cell motility and tumor invasion [48,49].
YES is part of the Scr kinase family [50] and its tyrosine kinase
activity has been shown to be elevated in colonic adenomas
compared to its activity in adjacent normal mucosa [51].
Furthermore YES activity was found to correlate with the
predicted cancer risk based on size, histology, and degree of
dysplasia [51]. Taken together, the present data suggests that
upregulation of YES is important for growth and transformation of
intestinal cells.
STAT proteins function downstream of JAKs and MAPKs,
which induce the dimerization of STAT proteins, thereby allowing
the translocation of STAT proteins into the nucleus [34,35].
STAT1 is best known for its pro-apoptotic role in response to
interferons, but STAT1 has also been reported to have a pro-
survival role in some cancers [35]. We observed a downregulation
of STAT1 on the transcript level and protein level upon miR-145
overexpression. Furthermore, we show that this downregulation of
STAT1 translates into an effect on the expression level of potential
STAT1 targets. This is the case for genes both positively and
negatively regulated by STAT1, but the effect is the greatest in
genes negatively regulated by STAT1. Even though STAT1 has
been reported both as a transcriptional activator and repressor, the
main mechanism of STAT1 transcriptional regulation is the
activation of its target genes [34]. Our findings suggest that
transcriptional repression is more widespread than recognized
previously. To sum up, transcription factor analyses of the
promoters of deregulated genes provides a means to characterize
secondary effects as previously published for miR-34a [52]. The
identified enrichment of STAT1 binding sites in promoters of
regulated genes demonstrates that secondary effects of miRNA
overexpression are pronounced already 24 hours post-transfec-
tion. Hence, it is important to consider secondary effects when
analyzing miRNA overexpression datasets.
In conclusion, using a microarray based approach we have
identified additional targets for the cancer-associated miRNA
miR-145 in colon cancer cells. The miRNA targets identified in
this study may serve to clarify the role of miR-145 in colon cancers
as well as other cancer types.
Table 2. Enriched 7mer words in the 39UTRs of down-
regulated transcripts.
Rank Word* z-Score FDR Annotation
1 AACTGGA 17.21 ,0.002 hsa-miR-145
2 CAGGAAA 16.76 ,0.002
3 CCAGGAA 13.94 ,0.002
4 ACTGGAA 13.88 ,0.002
5T ACTGGA 8.54 ,0.002
6A AACTGG 8.49 ,0.002
7 AATCCCA 8.19 ,0.002
8 ACTGGAT 7.91 ,0.002
9 TCAGGAA 7.85 ,0.002
10 TAACTGG 7.62 ,0.002
*Underlined sequences correspond to complete or partial miR-145 seed site
match.
doi:10.1371/journal.pone.0008836.t002
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Cell Cultures
DLD-1 cells were cultured in DMEM GlutaMAX
TM-I high
glucose medium (31966, Gibco Invitrogen) supplemented with
10% (v/v) fetal bovine serum (FBS, CH30160.03, Hyclone),
50 U/ml penicillin and 50 mg/ml streptomycin (P/S, 15140
Gibco Invitrogen) and incubated in 5% CO2 plus 20% oxygen.
HCT116 cells were cultured in McCoy’s 5A L-Glutamine
medium (22330, Gibco Invitrogen) supplemented with 10%
(v/v) FBS and P/S. Overexpression of miR-145 was achieved by
transfection with a miR-145 duplex that mimics the mature miR-
145 (PM11480; Ambion). Transfection with Caenorhabditis elegans
lin-4 duplex (PM10768, Ambion) or AllStar negative control
siRNA (1027281, Qiagen) was used as control. All transfections
were carried out using Lipofectamine
TM 2000 Transfection
Reagent (11668-019, Invitrogen) according to the manufactures
protocol. Unless otherwise stated cells were transfected with
50 nM of oligonucleotides. The transfection efficiency was
evaluated by transfection with the modified, fluorescent RNA
duplex siGLO Green Transfection Indicator (D-001630-01-20,
Dharmacon).
Quantitative RT-PCR
Total RNA was isolated with TRIZOL (15596-026, Invitrogen).
RNA samples for mRNA quantitative reverse transcription PCR
(RT-PCR) were treated with DNaseI (DNase-free kit
TM, Ambion,
AM1906). Quantitative PCR primers were designed using the
QuantPrime software [53] and sequences are listed in TABLE S2.
The levels of mRNAs were quantified using the comparative CT
method relative to levels of hypoxanthine phosphoribosyltrans-
fease (HPRT). Mature miR-145 levels were quantified using
TaqManH MicroRNA Assay (4373133, Applied Biosystems)
Quantification was normalized to the U6 small nuclear B non-
coding RNA (RNU6B) which served as an endogenous control
(4373381, Applied Biosystems).
Figure 3. Targets validation of YES and STAT1. A, Sequence alignment of the miR-145 seed region and mRNA targets. The position coordi-
nates are indicated for the transcript isoforms listed below. YES1 39UTR: ENSG00000176105:ENST0000035983 STAT1 cDNA: ENSG00000115415:
ENST00000361099. B, Firefly luciferase assay with pGL3+ constructs holding a 39UTR fragment of YES or a cDNA fragment of STAT1, downstream to
the firefly luciferase gene. Cells were co-transfected with firefly luciferase reporters along with a Renilla luciferase transfection control plasmid either
alone or with 50 nM miR-145 duplex and 50 nM AllStar duplex as a negative control. In pGL3+ mut vectors two base pairs in the miR-145 seed site
have been mutated. Luminescence was measured 24 hours post-transfection and the ratio of the firefly to the Renilla activity is shown relative
to transfection without RNA duplex and the empty vector. Data are shown as the mean 6 S.D. of four replicates. *, p,0.05 using a two-tailed t-test,
***, p,0.01 using a two-tailed t-test. C and D, Western blot analysis of DLD-1 and HCT116 cells transfected with miR-145 duplexes or mock
transfected cells blotted for YES (C) and STAT1 (D). Vinculin or tubulin were used as loading controls. The bands were quantified relative to the
appropriate loading controls using the TotalLab software and are shown relative to the protein level in mock transfected cells. The data shown are
representative of two experiments.
doi:10.1371/journal.pone.0008836.g003
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Cells were transfected with miR-145 duplex, AllStar negative
control or mock transfected as described above and seeded in 24-
well plates in four replicates the following day. For the crystal
violet growth curves, cells were washed twice in PBS and fixed by
addition of 1 ml 10% formalin to each well for 10 min., washed
twice in water and air-dried. The fixed cells were stained with
0.1% crystal violet solution by shaking incubation for 30 min.
Excess of crystal violet straining was removed by several washes
with water. The plates were allowed to dry and crystal violet was
extracted by addition of 250 ml to 1 ml of 10% acetic acid to each
well depending on the amount of crystal violet staining followed by
shaking incubation for 30 min. The amount of crystal violet
staining was quantified by measurement of the absorbance at
570 nm. The day after the cells were seeded in 24-well plates were
set to day 0 and used as a reference for the following days. For the
MTT assay cells were incubated with 0.5mg/ml MTT for four
hours. Following incubation the media removed and formazan
extracted by 90% isopropanol and 10% formic acid solution.
Absorbance was measured at 560 nm and reference wavelength at
750 nm was subtracted.
Microarray Profiles
DLD-1 cells were transfected with miR-145 duplex or mock
transfected in four biological replicates. Total RNA was isolated
with TRIZOL 24 hours after transfection. Affymetrix microarray
analysis (HG-U133 Plus 2.0 human) was performed at the
Microarray Centre, Rigshospitalet, Copenhagen University Hos-
pital as previously described [31]. Data processing and word
analysis are described in separate sections below.
Vector Construction and Reporter Assays or Plasmid
Vectors
The miR-145 pMIR-REPORT luciferase reporter vector was
cloned by inserting a oligo with perfect complementarity to mature
miR-145 into the HindII/SpeI site of pMIR-REPORT Luciferase
vector (AM5795, Applied Biosystems). Antisense and sense
oligonucleotide sequences (with restriction overhangs) are as
follow:
miR-145 AS: 59-CTAGTAGGGATTCCTGGGAAAACTG-
GACGCTCAGCA-39,
miR-145 S: 59-AGCTTGCTGAGCGTCCAGTTTTCCCA-
GGAATCCCTA-39,
The antisense and sense oligonucleotides were annealed in 50 ml
reactions containing 20 mM oligos in annealing buffer (30 mM
HEPES-KOH pH 7.4, 100 mM KCl, 2 mM MgCl2,5 0 m M
NH4Ac) prior to restriction and ligation into the pMIR-REPORT
vector.
39 UTR fragment of YES was PCR amplified from DLD-1
genomic DNA and cloned into the pGL3 control vector with a
multiple cloning site inserted downstream of the luciferase gene
(here called pGL3+) described previously [31]. An approximate
800bp fragment of STAT1 cDNA containing miR-145 seed site
were cloned from total DLD-1 cDNA. The primer sequences used
for PCR amplification were as follows (restriction sites indicated in
lower case):
YES 39UTR BglII FW: 59- GGGagatctATGCACAAATCT-
GCCAAAAT-39
YES 39UTR XhoI RV: 59- GGGctcgagCATTTCCCCTTT-
GATTGGAC -39
STAT1 cDNA BglII FW: 59- GGGagatctTGGGCTCAGCTT-
TCAGAAGT-39
STAT1 cDNA XhoI RV: 59- GGGctcgagAGGAAAACTGT-
CGCCAGAGA-39
The seed sites of miR-145 were mutated by substitution of two
nucleotides in the seed site using the QuikChange site-directed
mutagenesis kit (Stratagene) following the instructions of the
manufacturer. The miR-145 7mer AACTGGA was converted
into AACTCCA in the STAT1 vector and AAGAGGA in the
YES vector. Mutagenesis primers used were as follows:
STAT1 mut FW:59-CTTGATGGCCCTAAAGGAACTCCA-
TATATCAAGACTGAGTTGAT-39
STAT1 mut RV: 59-ATCAACTCAGTCTTGATATATG-
GAGTTCCTTTAGGGCCATCAAG-39
YES mut FW:59-TCTTCTTTACTCTGCATGTTTTTAAT-
GGTAAAGAGGAATCCCAGATATGGT -39
YES mut RV: 59-ACCATATCTGGGATTCCTCTTTACC-
ATTAAAAACATGCAGAGTAAAGAAGA -39
Luciferase Assays
Cells in 96-well plates were transfected with 100 ng/well pMIR-
REPORT and 25/well ng pRL-TK (E2241, Promega) together
with increasing amount of miRNA duplexes. Firefly and Renilla
luminescence was measured 24 hours after transfection using the
Dual-Glo luciferase kit (E2940, Promega). Non-transfected cells
were used for background subtraction and the ratio of lumines-
cence from the firefly reporter relative to the luminescence from
Table 3. Top 10 enriched or depleted transcription factor binding sites in the promoters of miR-145 responsive genes.
Down-regulated set
vs. no-change set Percentage Percentage P-value
Up-regulated set
vs. no-change set Percentage Percentage P-value
Down No-change Up No-change
STAT1 70% 51% 4.18?10
24 STAT1 66% 51% 1.34?10
24
FOXF2 86% 73% 3.86?10
23 IRF2 27% 36% 1.73?10
22
NFKB1 71% 84% 4.84?10
23 FOXF2 8% 73% 3.90?10
22
ATHB5 99% 91% 5.30?10
23 Lhx3 83% 77% 5.16?10
22
Lhx3 89% 77% 5.44?10
23 HMG-IY 99% 96% 6.76?10
22
Pax5 45% 59% 1.37?10
22 Staf 44% 51% 7.42?10
22
NF-kappaB 94% 99% 3.42?10
22 RELA 93% 96% 1.13?10
21
Staf 39% 51% 3.73?10
22 HNF1A 69% 63% 1.17?10
21
FOXD1 100% 96% 5.65?10
22 Pax5 65% 59% 1.19?10
21
doi:10.1371/journal.pone.0008836.t003
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validation of miR-145 targets DLD-1 cells/well were transfected
with 75ng/well pGL3+ firefly luciferase reporter constructs
together with 25 ng/well pRL-TK vector alone or with miR-
145 duplex or AllStar negative control.
Antibodies and Western Blot Analysis
For western blotting DLD-1 or HCT-116 cells were transfected
twice on two subsequent days. Cells were harvested 48 hours after
the first transfection, washed twice in PBS, and lysed in RIPA buffer
(150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS,
50 MTris-HCl at pH 8, 2 mM EDTA) containing protease
inhibitor cocktail (04693124001, Roche)) and phosphatase inhibi-
tors (1mM NaVO3, 10mM NaF and 1mM b-glycerolphosphat).
30mg protein/lane was separated on polyacrylamide gels, trans-
ferred to a nitrocellulose membrane and incubated with antibodies
against YES (2734, Cell Signaling) or STAT1 (9171, Cell Signaling)
or antibodies against Tubulin (ab11304, Abcam) or Vinculin
(V9131, Sigma) as a loading control. Band intensities were
quantified using TotalLab image analysis software.
Data Processing of Microarray Profiles
The expression data was processed using the ‘‘affy’’ package in
BioConductor in R [54]. Probe set intensities were summarized
using the Robust Multichip Average method and then trans-
formed to generalized log values with the variance stable VSN
method [55]. Due to different overall log2 intensity distribution
and problems with fitting of the microarray, the fourth mock
replicate array was removed prior to further analysis (FIGURE
S8). The probe sets for the remaining arrays were subsequently
mapped to Ensembl transcripts using the mappings provided by
BioMart. Probe sets that mapped to more than two different
Ensembl genes were discarded. For genes with more than one
probeset mapped to it, the probeset with the largest inter quartile
range of expression intensity was selected. Non-specific filtering
was used to remove genes with low variance between arrays using
a cutoff of 0.25. This left 2963 genes that were used for the
following analysis. Differentially expressed genes were found using
limma [56]. The p-values were corrected for multiple testing using
the Benjamini and Hochberg’s method to control the false
discovery rate and genes were divided into up, down and no-
change sets. Histograms of the logFC distributions before and after
non-specific filtering are shown in FIGURE S8. As seen from
FIGURE S8F the logFC distribution was displaced towards the
up-regulated genes with a mean logFC of 0.226 after non-specific
filtering. The reason for this displacement is not known, but it is
most likely due to a technical artefact since the displacement is
present in the logFC distributions before non-specific filtering.
Genes with a FDR,0.25 were taken as either up- or down-
regulated based on their log2 fold-change (logFC). A third set of
genes that do not change from control to experiment was defined
by selecting genes with FDR.0.8. The microarray data is
MIAME compliant and have been deposited in the GEO database
under the accession number: GSE18625.
Seed Site Enrichment
For the analysis of seed site enrichment, miRNA sequences from
miRBase (Release 12.0: Sept 2008) were used. 39UTR sequences
were retrieved using BioMart. For 39UTRs with more than one
transcript isoform the longest isoform was used. The 39UTRs of
the transcripts were scanned for matching 6mers, 7mers, 7mer-
1As and 8mers (perfect 8-nucleotide match). In the definition used,
seed sites are not contained in each other. This means that a 7mer,
7mer-1A or 8mer seed sites do not count as 6mer sites,
corresponding to the definition used by TargetScan (http://
www.targetscan.org/). In addition to the seed site enrichment
reported as percents of transcripts in each set with seed matches,
the seed site enrichment was also calculated as simple seed site
counts after correcting the up, down and no-change sets to have
the same size (scaling down the sets to the size of the smallest). In
order to check that the seed site enrichment is not due to
difference in 39UTR length in the up, down and no-change sets,
the seed site enrichment analysis was also performed where the
seed site occurrences were counted per kb. The difference in the
number of seed sites in transcripts from the up, down, and no-
change sets was evaluated testing the null hypothesis that the
proportions (probabilities of success) in the up, down, and no-
change set are the same. Enriched functions and diseases
associated with genes with a logFC above 1.1 or below -1.1 were
found using the Ingenuity Pathways Analysis
TM (IPA) release 8.0
(IngenuityH Systems, www.ingenuity.com).
Unbiased Word Analysis
We used a non-parametric statistical framework for scoring and
ranking oligonucleotide words based on their overrepresentation
in a ranked list of sequences. Our implementation closely follows a
method for inferring miRNA activities in gene expression data that
has previously been described by Cheng and Li [57]. We modified
the original method by Cheng and Li in three areas. 1) While
Cheng and Li only assess miRNA target sites, our implementation
evaluates all words of a given length. 2) Cheng and Li aggregate
miRanda target site scores per 39UTR as a continuous measure for
miRNA targeting, but because we evaluate all words we compute
an overrepresentation score of a given word in 39UTR sequence.
For a given sequence and word, we estimate a p-value for the null
hypothesis that the number of observed word occurrences m can
be explained by the length and nucleotide composition of the
sequence. The null distribution of word occurrences P(m) is
estimated from 5000 mononucleotide permutations of the original
sequence. The p-value, converted into a log-odds score, can be
directly estimated by: s~{log10(N(m)z1)=(5000z1), where
N(m) is the number of shuffles where the word occurred m times or
more. We add 1 as a crude correction for sampling uncertainty
and to avoid log(0). 3) Finally, we calculated the running sum
directly from overrepresentation scores (without weighing by
absolute expression changes). This simpler statistic was found to
work well in on public domain data sets (data not shown). Similar
to Cheng and Li, we obtained a false discovery rate for each word
by comparing word z-scores with z-scores calculated from all
permutations of the ranked list of 39UTRs.
Motif Search for Overrepresented Transcription Factor
Binding Sites
The promoter regions (2000bp upstream to the transcription
start site) of the up, down and no-change sets were retrieved using
BioMart and used to search for transcription factor binding sites as
defined in the JASPAR CORE database [37]. All 123 core
transcription factor binding count matrices were downloaded from
the JASPAR website (http://jaspar.cgb.ki.se/). The count matri-
ces were log-transformed into position specific weight matrices
(PSSMs) using a background nucleotide frequency of 25% and
pseudocount of 1. The search for matches to these PSSMs in the
promoter sequences were performed with the Asap software
package [58] using a threshold of 0.8. The percentage of
promoters with hits for a given transcription binding site was
compared between the down and the no-change sets or between
the up and no-change sets. The p-values were calculated testing
the null-hypothesis that the proportion of promoters with hits for a
Targets of MicroRNA-145
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Supporting Information
Figure S1 miR-145 expression profile. Endogenous expression
levels of miR-145 determined by miRNA quantitative RT-PCR.
The expression levels are shown relative to the non-coding RNA
U6 which serves as an endogenous control. Data are shown as the
mean 6 S.D. of three replicates.
Found at: doi:10.1371/journal.pone.0008836.s001 (0.01 MB
PDF)
Figure S2 Validation of miR-145 overexpression. Firefly
luciferase reporter containing a miR-145 (pMIR-145-REPORT)
complementary site (perfect antisense sequence) was co-transfected
with a Renilla luciferase transfection control plasmid and the
indicated amounts of miRNA duplexes in DLD-1 cells (A) and
HCT-116 cells (B). Transfection with lin-4 was used as a non-
specific control. Luminescence was measured 24 hours post-
transfection and the firefly luciferase activity was normalized to
the activity of the co-transfected Renilla plasmid. Data are shown
as the mean 6 S.D. of four replicates.
Found at: doi:10.1371/journal.pone.0008836.s002 (0.01 MB
PDF)
Figure S3 MTT cell proliferation assay. DLD-1 cell proliferation
as measured by MTT assay upon transfection with 50 nM miR-145
duplex, 50 nM AllStar negative control or mock transfection. Data
are shown as the mean 6 S.D. of four replicates.
Found at: doi:10.1371/journal.pone.0008836.s003 (0.01 MB
PDF)
Figure S4 Seed site enrichment reported per kb and as counts.
A, Seed site occurrences in the 39UTRs of up, down and no-
change transcripts for miR-145 presented per kb. The p-values
were calculated as described in FIGURE 2. P-values for 7mer seed
site enrichment were 2.3.10-28 (dn vs. up) and 5.1.10-7 (dn vs. nc).
P-values for 7mer-1A seed site enrichment were 1.3.10-14 (dn vs.
up) and 8.7.10-4 (dn vs. nc). B, Seed site occurrences in the
39UTRs of up, down and no-change transcripts for miR-145 after
correction of the up, down and no-change gene sets to the same
size (scaling down the sets to the size of the smallest). The p-values
were calculated as described in FIGURE 2. P-values for 7mer seed
site enrichment were 3.7.10-13 (dn vs. up) and 1.7.10-8 (dn vs. nc).
P-values for 7mer-1A seed site enrichment were 1.4.10-7 (dn vs.
up) and 1.2.10-5 (dn vs. nc).
Found at: doi:10.1371/journal.pone.0008836.s004 (0.01 MB
PDF)
Figure S5 Seed site enrichment reported for cDNA sequences,
coding regions and 59UTRs. The percentage of genes in the up,
down and no-change sets with seeds sites calculated for the entire
cDNA sequences (A), coding regions (B) and 59UTRs (C). P-values
for 7mer seed site enrichment in cDNA sequences were 7.7.10-10
(dn vs. up) and 1.3.10-3 (dn vs. nc). P-values for 7mer-1A seed site
enrichment were 6.7.10-6 (dn vs. up) and 1.5.10-3 (dn vs. nc).
Found at: doi:10.1371/journal.pone.0008836.s005 (0.01 MB
PDF)
Figure S6 6mer unbiased word analysis. A, Running sum of the
overrepresentation score for the miR-145 6mer seed site in the
ranked list of 39UTR sequences (black line) compared to
permutations of the ranked gene list (red lines). B, Top 10
enriched 6mer words in the 39UTRs among the down-regulated
transcripts.
Found at: doi:10.1371/journal.pone.0008836.s006 (0.41 MB
PDF)
Figure S7 Enrichment of putative STAT1 binding sites in the
promoters of up- and down-regulated genes. Binding motif for
STAT1 as defined in the JASPAR database (A). Overrepresen-
tation of STAT1 binding sites compared to a shuffled STAT1
binding site in promoters of down-regulated (B) and up-regulated
(C) genes compared to promoters of genes with no change in
expression level.
Found at: doi:10.1371/journal.pone.0008836.s007 (0.10 MB
PDF)
Figure S8 Microarray quality and processing. Histogram of raw
log intensities for individual arrays before normalization (A).
Boxplot of log intensities after normalization (B). The fit of the
vsnrma model used to normalize the arrays were evaluated by
calculation of normalized unscaled standard errors (C) together
with relative log expression (RLE) plots showing the log expression
for each probeset on each chip, relative to the median value for
that probeset (D). Histogram of the log fold-change (logFC)
distribution before (E) and after (F) non-specific filtering.
Found at: doi:10.1371/journal.pone.0008836.s008 (0.06 MB
PDF)
Table S1 List of potential miR-145 targets (defined as
downregulated transcripts with at least one miR-145 7mer,
7mer-1A or 8mer seed site in their 39UTRs).
Found at: doi:10.1371/journal.pone.0008836.s009 (0.11 MB
DOC)
Table S2 Primer sequences used for quantitative RT-PCR.
Found at: doi:10.1371/journal.pone.0008836.s010 (0.03 MB
DOC)
Author Contributions
Conceived and designed the experiments: LHG AK AHL. Performed the
experiments: LHG AJ LBF JW. Analyzed the data: LHG AK AHL. Wrote
the paper: LHG. Commented on the manuscript: AJ LBF JW AK AHL.
References
1. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
2. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell
136: 215–233.
3. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in
cancer. Nat Rev Cancer 6: 259–269.
4. Flynt AS, Lai EC (2008) Biological principles of microRNA-mediated regulation:
shared themes amid diversity. Nat Rev Genet 9: 831–842.
5. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian
mRNAs are conserved targets of microRNAs. Genome Res 19: 92–105.
6. Hammond SM (2006) MicroRNAs as oncogenes. Curr Opin Genet Dev 16:
4–9.
7. Medina PP, Slack FJ (2008) microRNAs and cancer: an overview. Cell Cycle 7:
2485–2492.
8. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA
expression signature of human solid tumors defines cancer gene targets. Proc
Natl Acad Sci U S A 103: 2257–2261.
9. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, et al. (2004) MicroRNA
profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc
Natl Acad Sci U S A 101: 11755–11760.
10. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread
deregulation of microRNA expression in human prostate cancer. Oncogene
27: 1788–1793.
11. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, et al. (2007)
MicroRNA expression profiling in prostate cancer. Cancer Res 67: 6130–6135.
12. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, et al. (2009)
Identification of novel microRNA targets based on microRNA signatures in
bladder cancer. Int J Cancer 125: 345–352.
Targets of MicroRNA-145
PLoS ONE | www.plosone.org 9 January 2010 | Volume 5 | Issue 1 | e883613. Akao Y, Nakagawa Y, Naoe T (2007) MicroRNA-143 and -145 in colon cancer.
DNA Cell Biol 26: 311–320.
14. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, et al. (2006)
Identification by Real-time PCR of 13 mature microRNAs differentially
expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 5: 29.
15. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP, James RJ (2003)
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol
Cancer Res 1: 882–891.
16. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, et al. (2009) p53 represses c-Myc
through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A
106: 3207–3212.
17. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, et al.
(2008) Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer
Res 68: 6416–6424.
18. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, et al. (2007)
Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to
clinicopathologic features of colorectal cancer. Oncology 72: 397–402.
19. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, et al. (2007) MicroRNA
signatures in human ovarian cancer. Cancer Res 67: 8699–8707.
20. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, et al. (2008) MicroRNA
expression profiles in serous ovarian carcinoma. Clin Cancer Res 14:
2690–2695.
21. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T (2007) Downregulation of
microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 98: 1914–1920.
22. Nakagawa Y, Iinuma M, Naoe T, Nozawa Y, Akao Y (2007) Characterized
mechanism of alpha-mangostin-induced cell death: caspase-independent apo-
ptosis with release of endonuclease-G from mitochondria and increased miR-
143 expression in human colorectal cancer DLD-1 cells. Bioorg Med Chem 15:
5620–5628.
23. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human
microRNA genes are frequently located at fragile sites and genomic regions
involved in cancers. Proc Natl Acad Sci U S A 101: 2999–3004.
24. Akao Y, Nakagawa Y, Naoe T (2006) let-7 microRNA functions as a potential
growth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903–906.
25. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, et al. (2007) Micro
RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of
colon cancer cells. J Biol Chem 282: 32582–32590.
26. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, et al. (2009)
Modulation of microRNA processing by p53. Nature 460: 529–533.
27. La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, et al. (2009) Mechanism of
growth inhibition by MicroRNA 145: the role of the IGF-I receptor signaling
pathway. J Cell Physiol 220: 485–491.
28. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (2009)
MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency
in human embryonic stem cells. Cell 137: 647–658.
29. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, et al. (2009) miR-
145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 460:
705–710.
30. Xin M, Small EM, Sutherland LB, Qi X, McAnally J, et al. (2009) MicroRNAs
miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of
smooth muscle cells to injury. Genes Dev 23: 2166–2178.
31. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, et al. (2008)
Programmed cell death 4 (PDCD4) is an important functional target of the
microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026–1033.
32. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, et al. (2003) Fascin, an
actin-bundling protein, modulates colonic epithelial cell invasiveness and
differentiation in vitro. Am J Pathol 162: 69–80.
33. Kalabis J, Rosenberg I, Podolsky DK (2006) Vangl1 protein acts as a
downstream effector of intestinal trefoil factor (ITF)/TFF3 signaling and
regulates wound healing of intestinal epithelium. J Biol Chem 281: 6434–6441.
34. Horvath CM (2000) STAT proteins and transcriptional responses to
extracellular signals. Trends Biochem Sci 25: 496–502.
35. Kim HS, Lee MS (2007) STAT1 as a key modulator of cell death. Cell Signal
19: 454–465.
36. Johnson M, Sharma M, Henderson BR (2009) IQGAP1 regulation and roles in
cancer. Cell Signal.
37. Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B (2004)
JASPAR: an open-access database for eukaryotic transcription factor binding
profiles. Nucleic Acids Res 32: D91–94.
38. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, et al. (2009) MicroRNA
deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer
100: 1002–1011.
39. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, et al. (2007)
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in
human hepatocellular carcinoma. Cancer Res 67: 6092–6099.
40. Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, et al. (2009)
Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res
15: 1177–1183.
41. Akao Y, Nakagawa Y, Naoe T (2006) MicroRNAs 143 and 145 are possible
common onco-microRNAs in human cancers. Oncol Rep 16: 845–850.
42. Wang X, Tang S, Le SY, Lu R, Rader JS, et al. (2008) Aberrant expression of
oncogenic and tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS ONE 3: e2557.
43. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, et al. (2007)
MicroRNA targeting specificity in mammals: determinants beyond seed pairing.
Mol Cell 27: 91–105.
44. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, et al. (2005)
Microarray analysis shows that some microRNAs downregulate large numbers
of target mRNAs. Nature 433: 769–773.
45. Nielsen CB, Shomron N, Sandberg R, Hornstein E, Kitzman J, et al. (2007)
Determinants of targeting by endogenous and exogenous microRNAs and
siRNAs. Rna 13: 1894–1910.
46. Sahin U, Blobel CP (2007) Ectodomain shedding of the EGF-receptor ligand
epigen is mediated by ADAM17. FEBS Lett 581: 41–44.
47. Santoro MM, Samuel T, Mitchell T, Reed JC, Stainier DY (2007) Birc2 (cIap1)
regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet 39:
1397–1402.
48. Barraclough J, Hodgkinson C, Hogg A, Dive C, Welman A (2007) Increases in
c-Yes expression level and activity promote motility but not proliferation of
human colorectal carcinoma cells. Neoplasia 9: 745–754.
49. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, et al. (2008) Yes
and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:
235–248.
50. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family
kinases. Annu Rev Cell Dev Biol 13: 513–609.
51. Pena SV, Melhem MF, Meisler AI, Cartwright CA (1995) Elevated c-yes
tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology
108: 117–124.
52. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, et al. (2009) p53-
independent upregulation of miR-34a during oncogene-induced senescence
represses MYC. Cell Death Differ.
53. Arvidsson S, Kwasniewski M, Riano-Pachon DM, Mueller-Roeber B (2008)
QuantPrime–a flexible tool for reliable high-throughput primer design for
quantitative PCR. BMC Bioinformatics 9: 465.
54. Gentleman R, Carey V, Huber W, Hu T, Irizarry R, et al. (2005) Bioinformatics
and Computational Biology Solutions Using R and Bioconductor. New York:
Springer-Verlag. 473 p.
55. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron M (2002)
Variance stabilization applied to microarray data calibration and to the
quantification of differential expression. Bioinformatics 18 Suppl 1: S96–104.
56. Smyth G (2005) Limma: linear models for microarray data. In: Gentleman RCV,
Dudoit S, Irizarry R, Huber W, eds. Bioinformatics and Computational Biology,
Solutions using R and Bioconductor. New York: Springer. pp 397–420.
57. Cheng C, Li LM (2008) Inferring microRNA activities by combining gene
expression with microRNA target prediction. PLoS ONE 3: e1989.
58. Marstrand TT, Frellsen J, Moltke I, Thiim M, Valen E, et al. (2008) Asap: a
framework for over-representation statistics for transcription factor binding sites.
PLoS One 3: e1623.
Targets of MicroRNA-145
PLoS ONE | www.plosone.org 10 January 2010 | Volume 5 | Issue 1 | e8836